Jorge D Machicado1, Anwar Dudekula2, Gong Tang3, Hongzhi Xu4, Bechien U Wu5, Chris E Forsmark6, Dhiraj Yadav7. 1. Division of Gastroenterology and Hepatology, Mayo Clinic Health System, Eau Claire, WI, USA. 2. Division of Gastroenterology, Saint Peter's University Hospital, New Brunswick, NJ, USA. 3. Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. 4. Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, FL, USA. 5. Center for Pancreatic Care, Division of Gastroenterology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA. 6. Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, FL, USA. 7. Division of Gastroenterology and Hepatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address: yadavd@upmc.edu.
Abstract
BACKGROUND: Prevalence estimates of chronic pancreatitis (CP) in the US are scarce. We aimed to determine the prevalence of CP in the commercially insured population of the US. METHODS: We analyzed the IQVIA Legacy PharMetrics database to calculate the period prevalence of CP from 2001 to 2013 among individuals with ≥1 year of enrollment. CP was defined as ≥1 healthcare contacts associated with a non-ancillary claim for a primary diagnosis of CP (ICD-9-CM 577.1). Prevalence estimates were age- and sex- adjusted to the 2010 US population. Sensitivity analysis was performed by using more stringent criteria: a) 1 claim of CP + [≥1 claims of acute pancreatitis (AP), CP or pancreatic cyst/pseudocyst]; b) 1 claim of CP + [≥1 claims for AP, CP or pancreatic cyst/pseudocyst in ≥3 months before or after the index CP claim]; c) ≥2 claims for CP; and d) ≥2 claims for CP separated by ≥ 6 months. RESULTS: Of 48.67 million eligible enrollees, 37,061 received the diagnosis of CP (mean age, 51.2 ± 15.2 years; 49% male). The age- and sex- adjusted period prevalence of CP per 100,000 was 73.4 (95% CI, 72.6-74.1), 98.7 (95% CI, 97.7-99.7) for adults and 8.3 (95% CI, 7.8-8.8) for children. Prevalence of CP was slightly higher in males (sex ratio, 1.05) and highest in the age group of 46-55 years (135/100,000). On sensitivity analysis, the prevalence of CP per 100,000 decreased to 60.2, 39.7, 38.8, and 18.8 with each of the alternative definitions. CONCLUSION: Prevalence estimates reported in our study provide an insight into the population burden of CP in the US. Published by Elsevier B.V.
BACKGROUND: Prevalence estimates of chronic pancreatitis (CP) in the US are scarce. We aimed to determine the prevalence of CP in the commercially insured population of the US. METHODS: We analyzed the IQVIA Legacy PharMetrics database to calculate the period prevalence of CP from 2001 to 2013 among individuals with ≥1 year of enrollment. CP was defined as ≥1 healthcare contacts associated with a non-ancillary claim for a primary diagnosis of CP (ICD-9-CM 577.1). Prevalence estimates were age- and sex- adjusted to the 2010 US population. Sensitivity analysis was performed by using more stringent criteria: a) 1 claim of CP + [≥1 claims of acute pancreatitis (AP), CP or pancreatic cyst/pseudocyst]; b) 1 claim of CP + [≥1 claims for AP, CP or pancreatic cyst/pseudocyst in ≥3 months before or after the index CP claim]; c) ≥2 claims for CP; and d) ≥2 claims for CP separated by ≥ 6 months. RESULTS: Of 48.67 million eligible enrollees, 37,061 received the diagnosis of CP (mean age, 51.2 ± 15.2 years; 49% male). The age- and sex- adjusted period prevalence of CP per 100,000 was 73.4 (95% CI, 72.6-74.1), 98.7 (95% CI, 97.7-99.7) for adults and 8.3 (95% CI, 7.8-8.8) for children. Prevalence of CP was slightly higher in males (sex ratio, 1.05) and highest in the age group of 46-55 years (135/100,000). On sensitivity analysis, the prevalence of CP per 100,000 decreased to 60.2, 39.7, 38.8, and 18.8 with each of the alternative definitions. CONCLUSION: Prevalence estimates reported in our study provide an insight into the population burden of CP in the US. Published by Elsevier B.V.
Authors: Christie Y Jeon; Robert Feldman; Felicity J Pendergast; Samer AlKaade; Randall E Brand; Nalini Guda; Bimaljit S Sandhu; Vikesh K Singh; C Mel Wilcox; Adam Slivka; David C Whitcomb; Dhiraj Yadav Journal: Pancreatology Date: 2020-10-12 Impact factor: 3.996
Authors: Samuel Y Han; Darwin L Conwell; Philip T Diaz; Amy Ferketich; Christie Y Jeon; Dhiraj Yadav; Phil A Hart Journal: Pancreatology Date: 2022-08-11 Impact factor: 3.977
Authors: Daniel M Spagnolo; Phil J Greer; Celeste Shelton Ohlsen; Shannon Mance; Mitchell Ellison; Cameron Breze; Ben Busby; David C Whitcomb; Mark Haupt Journal: Clin Transl Gastroenterol Date: 2022-01-19 Impact factor: 4.396
Authors: Søren S Olesen; Laust H Mortensen; Elisabeth Zinck; Ulrik Becker; Asbjørn M Drewes; Camilla Nøjgaard; Srdan Novovic; Dhiraj Yadav; Janne S Tolstrup Journal: United European Gastroenterol J Date: 2021-02-22 Impact factor: 4.623
Authors: Rebecca Troisi; Marianne Hyer; Linda Titus; Julie R Palmer; Elizabeth E Hatch; Dezheng Huo; Kjersti M Aagaard; William C Strohsnitter; Robert N Hoover Journal: J Dev Orig Health Dis Date: 2020-10-28 Impact factor: 3.034